Newsroom | 67786 results

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectoryY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today the appointment of Kevin Pojasek, Ph.D., to its Board of Directors. Dr. Pojasek brings more than two decades of expertise founding, scaling, and leading innovative biopharma companies, with deep expertise across corporate strategy, business development, and research and development. Dr. Pojasek is currently president and chief executive officer of...

CINCINNATI--(BUSINESS WIRE)--Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Ascent3T™ Neonatal Magnetic Resonance Imaging (MRI) System, a whole-body magnetic resonance scanner designed and optimized specifically for neonate and infant anatomy, including head, body, and extremities. “510(k) clearance marks a significant milestone for the company and reflects our mission to enable healthcare professionals to save more babies’ lives with st...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2025. "IQVIA closed 2025 with strong performance across all segments," said Ari Bousbib, chairman and CEO of IQVIA. "We delivered near double digit revenue and EPS growth, and the strongest...

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, the pioneer in translating real-world clinical data into personalized real-world evidence (RWE), announced the addition of two new hires to the leadership team, including the company's first Chief Technology Officer and Chief Financial Officer. The addition of these two team members expands the companies’ domain knowledge across the healthcare ecosystem including telehealth, payers and big tech. To further enhance the company's mission to clos...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025...

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results...

CHICAGO--(BUSINESS WIRE)--Adtalem Global Education (NYSE: ATGE) today announced it is changing its name to Covista, marking the culmination of a four-year transformation to become America's largest healthcare educator and an essential component of America’s healthcare workforce pipeline. The company's stock will begin trading under the ticker symbol CVSA on the New York Stock Exchange on February 24, 2026. "This is not simply a rebrand. It's recognition of what we've built and the problem we ar...

MINATO-KU, TOKIO, Japan & KOBE, Japan--(BUSINESS WIRE)--Fujirebio Holdings, Inc. (Zentrale: Minato-ku, Tokio; President & CEO: Goki Ishikawa; „Fujirebio“), eine konsolidierte Tochtergesellschaft der H.U. Group Holdings, Inc. (Zentrale: Minato-ku, Tokio; Chairman, President und Group CEO: Shigekazu Takeuchi) und die Sysmex Corporation (Zentrale: Kobe, Japan; President: Kaoru Asano, „Sysmex“) haben eine Vertriebskooperation für Demenztests vereinbart. Diese Vereinbarung ist das Ergebnis fortg...

日本東京港區及神戶--(BUSINESS WIRE)--(美國商業資訊)-- Fujirebio Holdings, Inc.（總公司：日本東京港區；總裁暨執行長：Goki Ishikawa；下稱「Fujirebio」）為H.U. Group Holdings, Inc.（總公司：日本東京港區；董事長、總裁兼集團執行長：Shigekazu Takeuchi）之合併子公司，其與Sysmex Corporation（總公司：日本神戶；總裁：Kaoru Asano；下稱「Sysmex」）已就失智症檢測達成銷售合作協議。此協議係基於雙方於2023年10月簽訂之「免疫分析領域業務合作基本協議」進行持續討論後所促成。1Sysmex將於雙方共同協議之地區與國家，獨家銷售Fujirebio之全自動Lumipulse®免疫分析系統及失智症相關試劑（下稱「本產品」）。未來，Fujirebio與Sysmex將共同合作，以因應治療藥物日益普及所伴隨之檢測需求增長，並將逐步擴展本產品之銷售國家/地區。 自2023年10月簽訂業務合作基本協議以來，雙方持續進行討論，旨在加速免疫分析之發展與全球拓展。2023年11...

MINATO-KU, TÓQUIO, Japão e KOBE, Japão--(BUSINESS WIRE)--A Fujirebio Holdings, Inc. (sede: Minato-ku, Tóquio; presidente e CEO: Goki Ishikawa; “Fujirebio”), uma subsidiária consolidada da H.U. Group Holdings, Inc. (sede: Minato-ku, Tóquio; presidente do conselho, presidente e CEO do grupo: Shigekazu Takeuchi) e a Sysmex Corporation (sede: Kobe, Japão; presidente: Kaoru Asano, “Sysmex”) chegaram a um acordo de colaboração comercial para testes de demência. Este acordo é resultado de discussões c...